176 related articles for article (PubMed ID: 29549189)
1. Brain microstructural injury occurs in patients with RRMS despite 'no evidence of disease activity'.
Harel A; Sperling D; Petracca M; Ntranos A; Katz-Sand I; Krieger S; Lublin F; Wang Z; Liu Y; Inglese M
J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):977-982. PubMed ID: 29549189
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of patients with relapsing-remitting multiple sclerosis using tract-based spatial statistics analysis: diffusion kurtosis imaging.
Li HQ; Yin B; Quan C; Geng DY; Yu H; Bao YF; Liu J; Li YX
BMC Neurol; 2018 Aug; 18(1):108. PubMed ID: 30086721
[TBL] [Abstract][Full Text] [Related]
3. Inclusion of the Symbol Digit Modalities Test in a revised assessment of 'no evidence of disease activity-4 (NEDA-4)' in Latin-American patients with multiple sclerosis.
Guevara C; Villa E; Diaz V; Garrido C; Martinez M; Orellana P; Alarcón P; Silva-Rosas C; Barker GJ; Kempton MJ; de Grazia J
Mult Scler Relat Disord; 2020 Jul; 42():102076. PubMed ID: 32361478
[TBL] [Abstract][Full Text] [Related]
4. Injury to white matter tracts in relapsing-remitting multiple sclerosis: A possible therapeutic window within the first 5 years from onset using diffusion-tensor imaging tract-based spatial statistics.
Asaf A; Evan S; Anat A
Neuroimage Clin; 2015; 8():261-6. PubMed ID: 26106550
[TBL] [Abstract][Full Text] [Related]
5. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
[TBL] [Abstract][Full Text] [Related]
6. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
Kappos L; De Stefano N; Freedman MS; Cree BA; Radue EW; Sprenger T; Sormani MP; Smith T; Häring DA; Piani Meier D; Tomic D
Mult Scler; 2016 Sep; 22(10):1297-305. PubMed ID: 26585439
[TBL] [Abstract][Full Text] [Related]
7. A Longitudinal Study of Disability, Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to Evidence of Disease Activity.
Nygaard GO; Celius EG; de Rodez Benavent SA; Sowa P; Gustavsen MW; Fjell AM; Landrø NI; Walhovd KB; Harbo HF
PLoS One; 2015; 10(8):e0135974. PubMed ID: 26280173
[TBL] [Abstract][Full Text] [Related]
8. Neural diffusion tensor imaging metrics correlate with clinical measures in people with relapsing-remitting MS.
Alshehri A; Al-Iedani O; Arm J; Gholizadeh N; Billiet T; Lea R; Lechner-Scott J; Ramadan S
Neuroradiol J; 2022 Oct; 35(5):592-599. PubMed ID: 35118885
[TBL] [Abstract][Full Text] [Related]
9. [Diffusion tensor imaging of the normal-appearing brain tissue in relapsing-remitting multiple sclerosis].
Yu CS; Li KC; Lin FC; Jiang TZ; Sun H; Chen B
Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1260-4. PubMed ID: 16796886
[TBL] [Abstract][Full Text] [Related]
10. Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.
Zivadinov R; Bergsland N; Hagemeier J; Tavazzi E; Ramasamy DP; Durfee J; Cherneva M; Carl E; Carl J; Kolb C; Hojnacki D; Weinstock-Guttman B
J Neurol Sci; 2018 Apr; 387():152-156. PubMed ID: 29571854
[TBL] [Abstract][Full Text] [Related]
11. Multiple white matter tract abnormalities underlie cognitive impairment in RRMS.
Yu HJ; Christodoulou C; Bhise V; Greenblatt D; Patel Y; Serafin D; Maletic-Savatic M; Krupp LB; Wagshul ME
Neuroimage; 2012 Feb; 59(4):3713-22. PubMed ID: 22062194
[TBL] [Abstract][Full Text] [Related]
12. Diffusion tensor imaging changes of the cortico-thalamic-striatal tracts correlate with fatigue and disability in people with relapsing-remitting MS.
Alshehri A; Koussis N; Al-Iedani O; Arm J; Khormi I; Lea S; Lea R; Ramadan S; Lechner-Scott J
Eur J Radiol; 2024 Jan; 170():111207. PubMed ID: 37988961
[TBL] [Abstract][Full Text] [Related]
13. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
[TBL] [Abstract][Full Text] [Related]
14. White matter microstructural alterations in clinically isolated syndrome and multiple sclerosis.
Huang J; Liu Y; Zhao T; Shu N; Duan Y; Ren Z; Sun Z; Liu Z; Chen H; Dong H; Li K
J Clin Neurosci; 2018 Jul; 53():27-33. PubMed ID: 29754967
[TBL] [Abstract][Full Text] [Related]
15. Histogram analysis of diffusion measures in clinically isolated syndromes and relapsing-remitting multiple sclerosis.
Yu CS; Lin FC; Liu Y; Duan Y; Lei H; Li KC
Eur J Radiol; 2008 Nov; 68(2):328-34. PubMed ID: 17928182
[TBL] [Abstract][Full Text] [Related]
16. No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany.
Huhn K; Senger D; Utz KS; Schmidt M; Fröhlich K; Waschbisch A; Seifert F; Dörfler A; Lee DH; Linker RA
Mult Scler Relat Disord; 2019 Jan; 27():133-138. PubMed ID: 30384198
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
[TBL] [Abstract][Full Text] [Related]
18. Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis.
Kern KC; Gold SM; Lee B; Montag M; Horsfall J; O'Connor MF; Sicotte NL
Neuroimage Clin; 2015; 8():440-7. PubMed ID: 26106524
[TBL] [Abstract][Full Text] [Related]
19. Quantitative evaluation of callosal abnormalities in relapsing-remitting multiple sclerosis using diffusion tensor imaging: A systemic review and meta-analysis.
Xu L; Chang SH; Yang L; Zhang LJ
Clin Neurol Neurosurg; 2021 Feb; 201():106442. PubMed ID: 33373835
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
